适配体BT200对小鼠心肌缺血再灌注损伤具有保护作用
研究在小鼠心肌缺血再灌注(MI/R)模型中探究抗血管性血友病因子(VWF)适配体BT200的心脏保护作用。C57BL/6小鼠缺血30分钟再灌注24小时,经静脉注射cy3标记BT200后,BT200可进入缺血心肌、抑制VWF A1活性并延长出血时间;BT200治疗组梗死面积显著减小、心功能改善,并减轻微血管阻塞、炎症反应和心肌细胞凋亡。作者认为靶向VWF的BT200可能成为急性心肌梗死的新治疗策略。
要点
- BT200可进入并浸润缺血心肌,抑制VWF A1活性并延长出血时间。
- BT200治疗组梗死面积显著减小、心功能改善。
- BT200减轻MI/R所致微血管阻塞、炎症反应和心肌细胞凋亡。
核心结论
- 药物靶向VWF的BT200可减轻小鼠急性MI/R损伤,可能成为急性心肌梗死的新治疗策略。
研究设计与样本
- C57BL/6小鼠行30分钟缺血和24小时再灌注建立MI/R模型,静脉注射cy3标记BT200后行活体成像,再经超声心动图、Evans三苯基四氮唑染色、组织病理学、蛋白质印迹和实时定量聚合酶链反应评估心脏损伤与炎症反应。
主要发现
- BT200适配体在24小时再灌注后可进入并浸润缺血心肌。
- BT200可抑制MI/R小鼠VWF A1活性并延长出血时间。
- BT200治疗组小鼠MI/R后梗死面积显著减小、心功能改善。
- BT200治疗可减轻MI/R诱导的微血管阻塞、炎症反应和心肌细胞凋亡。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myocardial ischemia-reperfusion (MI/R) injury tends to affect cardiac function and leads to poor patient prognosis, and there is still no effectively targeted drug to develop anti-von Willebrand factor (VWF) aptamer in acute coronary heart disease. However, the newly anti-VWF aptamer BT200 is applied not only for stroke and hemophilia but also for antithrombolism function in clinical development. The role of BT200 in acute myocardial injury during MI/R is still unknown. OBJECTIVES: To investigate the cardioprotective effect of aptamer BT200 in a mouse model of MI/R. METHODS: C57BL/6 mice were subjected to 30-minute ischemia and 24-hour reperfusion to establish MI/R model. Mice were treated with intravenous injection of cy3-labeled BT200 and were observed by an in vivo imaging system at different time points. Then, mice were sampled and evaluated by echocardiography, Evans triphenyltetrazolium chloride staining, histopathologic, western blotting, and real-time quantitative polymerase chain reaction assays to detect cardiac injury and inflammation response after 24-hour reperfusion. RESULTS: BT200 aptamer can enter and infiltrate into the ischemic myocardium after 24-hour reperfusion. BT200 was shown to inhibit VWF A1 activity and prolong bleeding time in MI/R mice. Moreover, BT200-treated mice had a significant reduction in infarct size and an improvement in cardiac function post-MI/R. BT200 treatment can also alleviate MI/R-induced microvascular obstruction, inflammation response, and cardiomyocyte apoptosis. CONCLUSION: Pharmacologic targeting of VWF with BT200 alleviates acute MI/R injury in a murine model and may be a novel therapy strategy for acute myocardial infarction.
引用
- Chen X, Liao X, Lu G, et al. Aptamer BT200 is protective against myocardial ischemia-reperfusion injury in mice. J Thromb Haemost. 2024. PMID: 39442622. doi:10.1016/j.jtha.2024.09.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。